Rhythm Pharmaceuticals (RYTM) Operating Income (2020 - 2025)
Historic Operating Income for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to -$52.7 million.
- Rhythm Pharmaceuticals' Operating Income fell 1997.95% to -$52.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$186.2 million, marking a year-over-year increase of 2986.91%. This contributed to the annual value of -$265.5 million for FY2024, which is 4401.57% down from last year.
- Rhythm Pharmaceuticals' Operating Income amounted to -$52.7 million in Q3 2025, which was down 1997.95% from -$45.3 million recorded in Q2 2025.
- Rhythm Pharmaceuticals' 5-year Operating Income high stood at -$34.4 million for Q1 2021, and its period low was -$139.9 million during Q1 2024.
- Over the past 5 years, Rhythm Pharmaceuticals' median Operating Income value was -$44.2 million (recorded in 2021), while the average stood at -$49.7 million.
- Per our database at Business Quant, Rhythm Pharmaceuticals' Operating Income plummeted by 16629.42% in 2024 and then soared by 6639.86% in 2025.
- Quarter analysis of 5 years shows Rhythm Pharmaceuticals' Operating Income stood at -$51.0 million in 2021, then rose by 17.43% to -$42.1 million in 2022, then grew by 1.99% to -$41.3 million in 2023, then rose by 0.02% to -$41.3 million in 2024, then decreased by 27.63% to -$52.7 million in 2025.
- Its Operating Income was -$52.7 million in Q3 2025, compared to -$45.3 million in Q2 2025 and -$47.0 million in Q1 2025.